LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. (“NantCell”), together with NantCell's parent company ImmunityBio, Inc. (“ImmunityBio”), have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017. With the termination of the license agreement between LadRx and NantC.
European patent office awards CytRx patent for LADR platform CytRx Corporation (CYTR) said on Wednesday it had been awarded a patent by the European Patent Office that covers the incorporation of the LADR backbone in a variety of drug…
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding share
CytRx to absorb subsidiary Centurion BioPharma; former CEO retires from board CytRx (CYTR) said it would merge with its subsidiary Centurion BioPharma as the company looks to benefit from Centurion''s LADR platform, which is being developed for localized delivery…
Critical Review: CytRx (OTCMKTS:CYTR) versus Vaxcyte (NASDAQ:PCVX) Vaxcyte (NASDAQ:PCVX) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Analyst Recommendations This is a breakdown of recent ratings and price targets for Vaxcyte and CytRx, as []
Analyzing CytRx (OTCMKTS:CYTR) & Big Cypress Acquisition (OTCMKTS:BCYP) CytRx (OTCMKTS:CYTR) and Big Cypress Acquisition (OTCMKTS:BCYP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Institutional and Insider Ownership 0.1% of CytRx shares are owned by institutional investors. Comparatively, 60.2% []
Head to Head Comparison: REGENXBIO (NASDAQ:RGNX) versus CytRx (OTCMKTS:CYTR) CytRx (OTCMKTS:CYTR) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations. Institutional & Insider Ownership 0.1% of CytRx shares are held by institutional investors. Comparatively, 78.2% of REGENXBIO []